Avivo Biomedical Inc.

Imagine a world without blood type constraints

[Science in Vancouver @ScienceVancity]

Dr. Seyed Amirhossein Nasseri and tge Withers' lab (@withlabb) at @UBC are making waves with their latest publication! 🌊

Their work on identifying an alternative pathway for glycan degradation is featured on the latest @ImmunoPodcast episode!

🎧: https://t.co/GgGRitMB11

[Lizzie Aby, MD @LizzieAbyMD]

@PRahfeld of @ubcmsl / @AvivoBio presents fascinating data on proof of concept for blood group conversion for human kidneys using ex-vivo machine perfusion at #ATC2023SanDiego

[Hector Madariaga, MD FASN 🇲🇽 @HecmagsMD]

Very interesting talk on ABO incompatible kidney transplantation and blood group conversion of human kidneys with ex vivo machine perfusion. Potential to eliminate blood groups as a factor in donor kidney allocation. This can significantly shorten wait times.

#ATC2023SanDiego

[Andrew Bentall @AJBentall]

Conversion of kidneys to be universal donors. @PRahfeld #ATC2023SanDiego
Future opinions for solid organ transplantation @AvivoBio

[OBIO @OBIOscience]

📢We are thrilled to introduce the companies selected to present at the 2023 #OBIO Investment Summit in Toronto from February 8-10.

Learn more👇
https://t.co/aatRoujTMx

#OBIOInvestmentSummit #OIS2023 #OBIOInvestmentSummit2023 #healthcare #healthtech #lifesciences

[Life Sciences BC @lifesciences_bc]

Member Spotlight: @AvivoBio (formerly ABOzymes), a British Columbia-based preclinical-stage company, has identified enzymes that convert the cell surface antigens that determine a person’s blood group to group O, the universal donor type. https://t.co/SSdgIdeJtb

[Innovation UBC @innovationubc]

Meet the 18 teams taking the stage at the 2022 Venture Showcase!

We are excited for you to meet the ventures solving problems across climate, human health and social impact with new and returning ventures joining us at Robson Square Nov 23!

https://t.co/YtQMIptxDN

#VS22

[Life Sciences BC @lifesciences_bc]

@LumiraVentures @ubcentrepreneur Dr. John Coleman of @AvivoBio presented enzymes that convert the cell surface antigens that determine a person’s blood group to group O, so a person’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions.

[GenomeBC @GenomeBC]

Here’s a scary-good story: we’re funding an @AvivoBio project that is testing an innovative technology to convert A blood types to O – paving the way to universal blood and organ transplants. If successful, this would be a life-saving leap forward.

Have a🩸good #Halloween.

[Life Sciences BC @lifesciences_bc]

Invest in BC presented by @LumiraVentures begins Wednesday, November 2nd! At 3:00 pm PT, the fifth session will commence, and attendees will hear company pitches from the Biotechnology sector. More information and registration: https://t.co/jrzMoMQmOc

[Life Sciences BC @lifesciences_bc]

@AvivoBio is seeking a Technician, Process Development to support the development of upstream and downstream processes, as well as impurity assay development to support the ongoing development of bacterial-produced enzyme-based product. Link: https://t.co/5leYFSO6yL

[Avivo Biomedical Inc. @AvivoBio]

We are searching for a Process Development Technician to help us realize our vision of a world without blood type constraints!

https://t.co/umgQQyuhBg

[Life Sciences BC @lifesciences_bc]

Invest in BC presented by @LumiraVentures is happening on November 2nd and 3rd! Check out the companies that are presenting from the Biotech and Digital Health sectors. Register here: https://t.co/GnH7HYb90t

@Altumview
@AvivoBio
@ezPT_Tech_Ltd
@GelmaCompany
@VoxcellBio

[Avivo Biomedical Inc. @AvivoBio]

ABOzymes is now Avivo! Avivo means “from life and for life”. This name update reflects the evolution of the company, while maintaining our founding vision. Visit our new website: https://t.co/1HhlFavdR2 and be sure to play the video on the homepage.

[Avivo Biomedical Inc. @AvivoBio]

We’re hiring! We are looking for a Project Manager and a Technician to join us on our journey to make blood types obsolete for blood transfusions and organ transplants. Postings listed at the @lifesciences_bc job board https://t.co/uu5wyprgRY

[Joel Beasley @moderncto_io]

Peter Rahfeld, Co-founder & CSO at @ABOzymes, talks about transforming blood types by altering the antigens in the blood.

Check out the full episode now! https://t.co/RNoFODzxQd

#cto #medtech #innovation

[UBC Centre for Blood Research @CBR_UBC]

🧬CBR scientists & collaborators are paving the way to better #health w/ unique #genomics projects, supported by the @GenomeBC Pilot Innovation Fund.

Dr. Karen Cheung: Isolatrix
Dr. Jayachandran Kizhakkedathu: Converting blood group for #transplant

More: https://t.co/Uy2YekwIxp

[Avivo Biomedical Inc. @AvivoBio]

Thanks @GenomeBC for joining us on our journey to #makebloodtypesobsolete!

[GenomeBC @GenomeBC]

Our Pilot Innovation Fund offers investment& provides mentorship!

We're delighted to support Isolatrix (@UBC @BCCancer) GPS-seq (UBC) protein analysis tech (@ReuvenGordon @uvic) Tope-seq (BCCancer) & converting blood group for transplant (@ABOzymes)

More https://t.co/OMplGucTNY

[Science in Vancouver @ScienceVancity]

Dr. Spence Macdonald (@spencemacdon), VP of Product Development at @ABOzymes, recently discovered a new #biopolymer! 🧪

@WithLabb @AzoM
https://t.co/Y3g8UTB2AV

[adMare BioInnovations @adMare_Bio]

We're excited to welcome @ABOzymes, Cura Therapeutics, Damona pharma & @HDAXtx, the companies selected to present at our Emerging Co.'s Forum at @BIOTECanada's upcoming Investor Summit. adMare is all about building companies, and these 4 are ones to watch!https://t.co/RbNMvJCBs7